BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cullinan Therapeutics Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Cullinan Therapeutics Inc.'s drug
 s run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06566547-3438@assetmemo.bio
DTSTAMP:20261121T005944Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:Velinotamig (GR1803): Phase 2 readout est. (NCT06566547)
DESCRIPTION:Velinotamig (GR1803)\, phase 2\, Multiple Myeloma.\nStudy: GR18
 03 Injection in Patients With Relapsed/Refractory Multiple Myeloma\nEstima
 ted primary completion: 12 May 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/velinotamig-gr1803#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06566547
URL:https://assetmemo.bio/drug/velinotamig-gr1803#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07348055-3438@assetmemo.bio
DTSTAMP:20261121T005944Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Velinotamig (GR1803): Phase 1/2 readout est. (NCT07348055)
DESCRIPTION:Velinotamig (GR1803)\, phase 1/2.\nStudy: A Study of GR1803 in 
 Systemic Lupus Erythematosus\nEstimated primary completion: 1 June 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/velinotamig-gr1803#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0734805
 5
URL:https://assetmemo.bio/drug/velinotamig-gr1803#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952075-3438@assetmemo.bio
DTSTAMP:20261121T005944Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Velinotamig (GR1803): Phase 2 readout est. (NCT06952075)
DESCRIPTION:Velinotamig (GR1803)\, phase 2.\nStudy: GR1803 Injection in Pat
 ients With RRMM\nEstimated primary completion: 1 July 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/velinotamig-gr1803#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06952075
URL:https://assetmemo.bio/drug/velinotamig-gr1803#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07738822-3438@assetmemo.bio
DTSTAMP:20261121T005944Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Velinotamig (GR1803): Phase 1/2 readout est. (NCT07738822)
DESCRIPTION:Velinotamig (GR1803)\, phase 1/2.\nStudy: A Phase 1b/2a Study o
 f Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA\nEstimated 
 primary completion: January 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/velinotamig-gr1803#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07738822
URL:https://assetmemo.bio/drug/velinotamig-gr1803#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07452198-3438@assetmemo.bio
DTSTAMP:20261121T005944Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Velinotamig (GR1803): Phase 3 readout est. (NCT07452198)
DESCRIPTION:Velinotamig (GR1803)\, phase 3\, Multiple Myeloma.\nStudy: A St
 udy of GR1803 Injection Versus Daratumumab\, Pomalidomide\, and Dexamethas
 one (DPd) in Participants With Relapsed or Refractory Multiple Myeloma\nEs
 timated primary completion: March 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/velinotamig-gr1803#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07452198
URL:https://assetmemo.bio/drug/velinotamig-gr1803#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05143996-2986@assetmemo.bio
DTSTAMP:20261121T005944Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:CLN-049: Phase 1/2 readout est. (NCT05143996)
DESCRIPTION:CLN-049\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: CLN-049 i
 n Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelod
 ysplastic Syndrome (MDS)\nEstimated primary completion: 30 December 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/cln-049#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05143996
URL:https://assetmemo.bio/drug/cln-049#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
